PT1286674E - Composição para potenciar agentes quimioterapêuticos de cancro - Google Patents

Composição para potenciar agentes quimioterapêuticos de cancro Download PDF

Info

Publication number: PT1286674E
Authority: PT; Portugal
Prior art keywords: chemotherapeutic agents; composition; cancer chemotherapeutic; potentiating; potentiating cancer
Prior art date: 2000-09-01

Application number

PT01964398T

Other languages

English (en)

Inventor

Raxit J Jariwalla

Original Assignee

Ester C Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-01

Filing date

2001-08-24

Publication date

2008-08-21

2001-08-24 Application filed by Ester C Company filed Critical Ester C Company

2008-08-21 Publication of PT1286674E publication Critical patent/PT1286674E/pt

Links

239000002246 antineoplastic agent Substances 0.000 title abstract 2
230000003389 potentiating effect Effects 0.000 title 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-M L-ascorbate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CIWBSHSKHKDKBQ-JLAZNSOCSA-M 0.000 abstract 1
150000000994 L-ascorbates Chemical class 0.000 abstract 1
229930003268 Vitamin C Natural products 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002241 furanones Chemical class 0.000 abstract 1
229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
239000011707 mineral Substances 0.000 abstract 1
235000019154 vitamin C Nutrition 0.000 abstract 1
239000011718 vitamin C Substances 0.000 abstract 1
150000003700 vitamin C derivatives Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT01964398T 2000-09-01 2001-08-24 Composição para potenciar agentes quimioterapêuticos de cancro PT1286674E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/654,377 US6468980B1 (en)	2000-09-01	2000-09-01	Methods and compositions for potentiating cancer chemotherapeutic agents

Publications (1)

Publication Number	Publication Date
PT1286674E true PT1286674E (pt)	2008-08-21

Family

ID=24624611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT01964398T PT1286674E (pt)	2000-09-01	2001-08-24	Composição para potenciar agentes quimioterapêuticos de cancro

Country Status (15)

Country	Link
US (1)	US6468980B1 (pt)
EP (1)	EP1286674B1 (pt)
JP (1)	JP2004508335A (pt)
KR (1)	KR20030019297A (pt)
AT (1)	ATE400267T1 (pt)
AU (1)	AU8525401A (pt)
CA (1)	CA2389602A1 (pt)
CY (1)	CY1108787T1 (pt)
DE (1)	DE60134740D1 (pt)
DK (1)	DK1286674T3 (pt)
ES (1)	ES2309085T3 (pt)
MX (1)	MXPA02004327A (pt)
PT (1)	PT1286674E (pt)
TR (1)	TR200201192T1 (pt)
WO (1)	WO2002020023A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6878744B2 (en) *	1999-02-05	2005-04-12	Oxycal Laboratories, Inc.	Vitamin C compositions
CN1197561C (zh) *	2001-07-03	2005-04-20	北京巨能亚太生命科学研究中心	L－苏糖酸钙在制备预防或治疗损及软骨的疾病的药物中的用途
ATE444063T1 (de)	2003-08-13	2009-10-15	Ester C Company	Verfahren zur linderung von umweltbedingtem stress durch oxidationsmittel und regulierung vorteilhafter gene
MX2009008030A (es) *	2007-01-31	2009-10-19	Univ Rutgers	Liberacion controlada de activos en la piel.
KR101998246B1 (ko) *	2018-08-22	2019-07-10	주식회사 메타파인즈	금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
TR2022000209A2 (tr)	2022-01-07	2022-02-21	Oezge Gueven	Ozoni̇ze c-vi̇tami̇ni̇ i̇çeren bi̇r anti̇-kanser i̇laci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1987003481A1 (en) *	1985-12-05	1987-06-18	American Biotechnology Co., Ltd.	Anthracycline type antitumor agents with l-ascorbic acid
GB8810173D0 (en) *	1988-04-29	1988-06-02	Norsk Hydro As	Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
WO1990012571A1 (en) *	1989-04-07	1990-11-01	Oxycal Laboratories, Inc.	Compositions and methods for administering vitamin c
JPH08291075A (ja) *	1995-04-20	1996-11-05	Showa Denko Kk	癌転移阻害剤
EP0875246A1 (en) *	1997-04-04	1998-11-04	Showa Denko Kabushiki Kaisha	Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer
ES2274618T3 (es) *	1998-02-06	2007-05-16	The Ester C Company	Composiciones liquidas estables de ascorbato de calcio, y metodos de de preparacion y uso.
CA2348565A1 (en) *	1999-08-30	2001-03-08	Oxycal Laboratories, Inc.	Methods and compositions for selective cancer chemotherapy

2000
- 2000-09-01 US US09/654,377 patent/US6468980B1/en not_active Expired - Lifetime
2001
- 2001-08-24 AU AU85254/01A patent/AU8525401A/en not_active Abandoned
- 2001-08-24 ES ES01964398T patent/ES2309085T3/es not_active Expired - Lifetime
- 2001-08-24 AT AT01964398T patent/ATE400267T1/de not_active IP Right Cessation
- 2001-08-24 TR TR2002/01192T patent/TR200201192T1/xx unknown
- 2001-08-24 PT PT01964398T patent/PT1286674E/pt unknown
- 2001-08-24 JP JP2002524507A patent/JP2004508335A/ja active Pending
- 2001-08-24 DK DK01964398T patent/DK1286674T3/da active
- 2001-08-24 EP EP01964398A patent/EP1286674B1/en not_active Expired - Lifetime
- 2001-08-24 MX MXPA02004327A patent/MXPA02004327A/es active IP Right Grant
- 2001-08-24 DE DE60134740T patent/DE60134740D1/de not_active Expired - Lifetime
- 2001-08-24 CA CA002389602A patent/CA2389602A1/en not_active Abandoned
- 2001-08-24 KR KR1020027005605A patent/KR20030019297A/ko not_active Ceased
- 2001-08-24 WO PCT/US2001/026455 patent/WO2002020023A1/en not_active Ceased
2008
- 2008-09-23 CY CY20081101028T patent/CY1108787T1/el unknown

Also Published As

Publication number	Publication date
EP1286674B1 (en)	2008-07-09
DE60134740D1 (de)	2008-08-21
CA2389602A1 (en)	2002-03-14
DK1286674T3 (da)	2008-11-03
EP1286674A1 (en)	2003-03-05
TR200201192T1 (tr)	2003-05-21
WO2002020023A1 (en)	2002-03-14
ATE400267T1 (de)	2008-07-15
MXPA02004327A (es)	2002-11-07
CY1108787T1 (el)	2014-04-09
EP1286674A4 (en)	2005-12-21
AU8525401A (en)	2002-03-22
US6468980B1 (en)	2002-10-22
ES2309085T3 (es)	2008-12-16
JP2004508335A (ja)	2004-03-18
KR20030019297A (ko)	2003-03-06

Publication	Publication Date	Title
AU2795000A (en)	2000-07-12	Epothilone derivatives and their use as antitumor agents
AU2001282399A1 (en)	2002-03-22	Resorcinol derivatives
DE60112974D1 (en)	2005-09-29	Carbolinderivate
AU3652102A (en)	2002-06-11	Compounds and their uses
ES2184149T3 (es)	2003-04-01	Paclitaxeles 6-tio sustituidos.
MXPA03010134A (es)	2004-03-10	Derivados de ciclohexan-1-4-diamina sustituidos.
EA200100369A1 (ru)	2001-10-22	Химиотерапия рака с помощью ацетилдиналина в комбинации с гемцитабином, кэйпцитабином или цис-платиной
BG105967A (en)	2002-08-30	C(7) ester substituted taxanes and their use as antitumor agents
DE60216233D1 (en)	2007-01-04	Carbolinderivate
PL350027A1 (en)	2002-10-21	C10 heterosubstituted acetate taxanes as antitumor agents
CY1108787T1 (el)	2014-04-09	Συνθεση για ενισχυση χημειοθεραπευτικων παραγοντων καρκινου
MX9800945A (es)	1998-04-30	Uso de griseofulvina para inhibir el crecimiento de canceres.
TR200201245T2 (tr)	2004-08-23	Kanser tedavisi için onkolitik kombinasyonlar.
AP2001002274A0 (en)	2001-09-30	Rescorcinol derivatives.
WO2002080854A3 (en)	2002-12-05	Compositions and methods for the prevention and treatment of human prostate cancer
IL138688A0 (en)	2001-10-31	Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
BG105964A (en)	2002-08-30	C(10) carbonate substituted taxanes and their use as antitumor agents
AU2002211493A1 (en)	2002-05-15	Indole derivatives as pde5-inhibitors
AU3919001A (en)	2001-08-27	Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
DE69815100D1 (de)	2003-07-03	Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
BG105966A (en)	2002-07-31	C7 carbonate substituted taxanes and their application as antitumor agents
TR200302193T4 (tr)	2004-02-23	Kombinasyon kemoterapisi.
IL145640A0 (en)	2002-06-30	C10 carbamoyloxy substituted taxanes as antitumor agents
WO2001015777A8 (en)	2001-10-11	Pulmonary-administration of mineral ascorbates
DE69818492D1 (en)	2003-10-30	7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele